Planet Labs Free cash flow decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from -$17.90M to $0.00. Over 4 years (FY 2022 to FY 2026), Free cash flow shows an upward trend with a 2.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.04M | -$14.34M | -$14.76M | -$25.46M | -$9.40M | -$25.92M | -$32.81M | -$16.25M | -$36.94M | -$5.78M | -$30.25M | -$15.74M | -$14.24M | -$22.98M | -$3.56M | -$17.90M | $9.23M | $47.48M | $1.89M | $0.00 |
| QoQ Change | — | -804.6% | -3.0% | -72.4% | +63.1% | -175.9% | -26.6% | +50.5% | -127.3% | +84.4% | -423.7% | +48.0% | +9.6% | -61.4% | +84.5% | -403.2% | +151.6% | +414.6% | -96.0% | -100.0% |
| YoY Change | — | — | — | — | -561.7% | -80.8% | -122.3% | +36.2% | -293.2% | +77.7% | +7.8% | +3.1% | +61.5% | -297.9% | +88.2% | -13.7% | +164.8% | +306.6% | +153.1% | +100.0% |